{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-025626","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.974852+00:00","generated_at":"2026-05-26T06:14:44.083365+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revelation Biosciences regains Nasdaq compliance and advances PRIME Phase 1b CKD study","bullets":["Nasdaq confirmed REVB common stock meets minimum bid price and all continued listing requirements.","Company cannot use 180-day grace period if bid price falls below $1.00 again; would receive delisting letter but may request hearing.","PRIME Phase 1b study of Gemini IV in Stage 3-4 CKD patients has commenced, enrolling up to 40 patients across 5 cohorts.","CEO James Rolke highlighted Nasdaq listing for liquidity, capital access, and talent retention."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-025626","json":"https://secwatch.observer/filing/0000950170-25-025626.json","markdown":"https://secwatch.observer/filing/0000950170-25-025626.md","text":"https://secwatch.observer/filing/0000950170-25-025626.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025025626/0000950170-25-025626-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025025626/revb-20250219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:14:44.083365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}